Browsing tag:

Trastuzumab


Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]

Read More

J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]

Read More

A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]

Read More

What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders.   Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service